Reduced expression of TLR3, TLR10 and TREM1 by human macrophages in Chronic cavitary pulmonary aspergillosis, and novel associations of VEGFA, DENND1B and PLAT  by Smith, N.L.D. et al.
Reduced expression of TLR3, TLR10 and TREM1 by human macrophages
in Chronic cavitary pulmonary aspergillosis, and novel associations of
VEGFA, DENND1B and PLAT
N. L. D. Smith1,2,3,4,5, J. Hankinson2,3,4,5, A. Simpson2,3,4,5, D. W. Denning1,2,3,4,5,6 and P. Bowyer1,2,3,4,5
1) Manchester Fungal Infection Group (MFIG), 2) Faculty of Medical and Human Sciences, University of Manchester, 3) Manchester Academic Health Science
Centre, 4) University Hospital South Manchester NHS Foundation Trust, 5) NIHR South Manchester Respiratory and Allergy Clinical Research Facility,
and 6) National Aspergillosis Centre, University of South Manchester, Manchester, UK
Abstract
Chronic cavitary pulmonary aspergillosis (CCPA) is an uncommon but serious pulmonary disease of humans, with an annual mortality rate
of 10–30%. It is caused by the fungus Aspergillus fumigatus. Patients are overtly immunocompetent; however, some immunogenetic defect is
likely. To investigate this, we performed a genetic association study analysing biologically plausible candidate genes in 112 CCPA patients and
279 healthy controls, and investigated gene expression in monocyte-derived macrophages from patients and controls at baseline and during
stimulation with A. fumigatus. Single-nucleotide polymorphisms (SNPs) associated with CCPA were found in TLR1, CLEC7A (dectin-1), PLAT
(n = 2), VEGFA, and DENND1B. Macrophages from CCPA patients showed low TLR3 and TLR10 expression and high TREM1 expression at
baseline, as compared with macrophages from healthy subjects, with major expression differences being seen in most Toll-like receptors
(TLRs) during 9 h of co-culture with A. fumigatus. The differences in baseline expression between the healthy and CCPA groups suggest
roles for TLR3 and TLR10 in susceptibility to CCPA, and the association of SNPs in PLAT (n = 2), VEGFA and DENND1B supports novel roles
for plasminogen activation and angiogenesis and of these genes speciﬁcally in susceptibility to CCPA.
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Introduction
Aspergillus fumigatus is the primary cause of aspergillosis, of
which chronic cavitary pulmonary aspergillosis (CCPA) is one
of the most devastating manifestations [1]. Although uncom-
mon, CCPA is a serious disease affecting immunocompetent
people, most of whom have underlying lung disease (e.g.
previous tuberculosis (TB)) [2]. The pathogenesis of CCPA
remains enigmatic [1]. The formation, expansion and coales-
cence of pulmonary cavities is characteristic, and occurs over
months or years [1]. Cavities may contain a fungal ball
(aspergilloma). Without treatment, progressive lung and
pleural ﬁbrosis occurs [1]. Haemoptysis is common. Chronic
inﬂammation with localized ﬁbrosis without granulomas,
necrosis or eosinophilic inﬁltration is seen microscopically in
the cavity wall, and localized networks of additional small
blood vessels are generated in proximity to the cavity;
however, the mechanisms behind these pathologies are
unclear.
A. fumigatus interacts with the human host via pathogen
recognition receptors on the surfaces of immune cells such as
macrophages and neutrophils [3]. These receptors include the
Toll-like receptors (TLRs), particularly TLR2, TLR4, and TLR9,
but also perhaps TLR1, TLR3, and TLR6 [4,5], and the b-glucan
receptor, dectin-1 [3,6]. Triggering receptor expressed on
myeloid cells 1 (TREM1) is found on neutrophils and mono-
cytes, and ampliﬁes the inﬂammation induced by stimulation of
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TLRs, including TLR2 and TLR4 [7,8]. In addition, A. fumigatus
can be bound by other host proteins, including plasminogen
[9]. Th1 responses (e.g. tumour necrosis factor-a (TNF-a))
appear to be beneﬁcial, wheras uncontrolled Th2 responses
are detrimental [3]. DENN/MADD domain containing 1B
(DENND1B) is a negative regulator of the TNF-a receptor
(TNFR1) [10]. Furthermore, angiogenesis has been shown to
be inhibited by A. fumigatus, and inhibition of vascular endo-
thelial growth factor A (VEGFA) may increase susceptibility to
invasive aspergillosis (IA) [11,12].
The role of these receptors and molecular mediators in
susceptibility and disease development in CCPA remains
unclear. Small genetic association studies have found CCPA
to be associated with TNF, MBL2, TGFB1, IL15, TLR4, and IL10,
but further work is required [13–16]. In addition, single-nucle-
otide polymorphisms (SNPs) in the plasminogen gene (PLG)
have been associated with IA, but have not been investigated in
CCPA [9,17]. We performed a much larger candidate gene
association study of CCPA, extensively genotyping SNPs in
genes involved in the recognition of A. fumigatus, as well as
SNPs in PLG, the plasminogen activator gene (PLAT), VEGFA,
and DENND1B. In addition, we compared the expression of
TLR genes by monocyte-derived macrophages (MDMs) from
CCPA patients and controls, at baseline and during co-culture
with A. fumigatus.
Materials and Methods
See Appendix S1 for further details.
Subjects
CCPA patients and healthy subjects are deﬁned in Appen-
dix S1. As described previously [18], CCPA patients were
recruited between March 2006 and August 2010 from the
National Aspergillosis Centre (NAC) in Manchester (NAC,
University Hospital of South Manchester, UK). Those cases
complicated by other forms of aspergillosis were excluded.
Previously recruited healthy subjects were used [19]. The
Local Research Ethics Committee approved the study, and
written informed consent was obtained for all subjects.
DNA and peripheral blood mononuclear cell extraction
DNA and peripheral blood mononuclear cells were extracted
from blood as described previously [18].
Macrophage–A. fumigatus co-culture
MDMs were generated, live A. fumigatus conidia were added
(4 9 105/well) and RNA was extracted as described previ-
ously [18].
Measuring expression by MDMs
The human innate and adaptive immune responses RT2
proﬁler PCR array (SABiosciences, Qiagen Ltd., Crawley,
UK) was used to measure expression of TLR1, TLR2, TLR3,
TLR4, TLR9, TLR10 and TREM1 in pooled RNA samples
(1 lg) from each group (n = 10 subjects). HRPT1, RPL13A
and GAPDH were used as housekeeping normalizer
genes. Fold changes were calculated relative to the healthy
average at 0 h with the manufacturer’s online analysis
tool (http://pcrdataanalysis.sabiosciences.com/pcr/arrayanaly
sis.php).
Gene and SNP selection for genotyping
Haplotype tagging SNPs (n = 141) in 13 biologically plausible
and/or previously associated candidate genes were identiﬁed by
use of the Genome Variation Server (http://gvs.gs.washington.
edu/GVS/) (Table S1). Sequenom genotyping was completed
for 134 SNPs. After quality control and exclusion of redundant
or monomorphic SNPs, 109 SNPs were analysed with Stata
(Statacorp LP, College Station, TX, USA). Logistic regression
was used to determine association using dominant and
recessive models. The Benjamini–Hochberg correction for
the false discovery rate was used to correct for multiple
testing.
Statistical analysis
Statistical analysis was performed in GraphPad Prism
(Version 5.02; GraphPad Software Inc., La Jolla, CA, USA),
Stata, and SPSS (Version 16; SPSS Inc., Chicago, IL, USA). Ages
and percentages of males were not normally distributed, and
were compared by the use of Mann–Whitney tests. Statisti-
cal analysis with t-tests, repeated measures one-way ANOVA
and two-way ANOVA was performed for analysis of expression
data.
Results
Characteristics of the study population
Of the 396 Caucasian subjects selected for genotyping (116
CCPA; 280 healthy), 391 were genotyped successfully (112
CCPA; 279 healthy). The majority of CCPA patients had
one or more underlying diseases (Table 1). The CCPA group
was older than the healthy group (median age: 64.9 years
vs. 47.0 years, p <0.0001) and contained a higher pro-
portion of males (60.7% vs. 40.1%, p 0.0005; Table 1). These
characteristics were similar in the subset of individuals
used for gene expression studies, and these are consid-
ered to be representative of the total study population
(Table 2).
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, O960–O968
CMI Smith et al. TLR genes and novel associations in CCPA O961
Expression of TLR genes differs between MDMs from CCPA
patients and those from healthy subjects
Baseline expression of TLR3 (2.35-fold, p 0.003) and TLR10
(2.63-fold, p 0.0001) was signiﬁcantly lower in MDMs from
CCPA patients than in those from healthy subjects. After
stimulationwith A. fumigatus, expression of TLR10 changed little,
and remained lower in the CCPA group at all time-points (the
change over timewas not signiﬁcantly different between the two
groups), whereas expression of TLR3 remained lower in the
CCPA group up to 6 h (Fig. 1), after which expression in the
healthy group decreased to the level in the CCPA group by 9 h.
Baseline expression of TLR2, TLR4 and TLR9 was only
marginally different (less than two-fold) between the CCPA
and healthy groups, and expression remained similar, although
slightly higher in the CCPA group, during the ﬁrst 6 h of
stimulation with A. fumigatus. By the 9 h time-point, dramatic
differences were observed; in the CCPA group, expression
continued to be relatively stable, whereas in the healthy group
expression decreased (TLR2 and TLR4) or increased (TLR9)
dramatically (Fig. 1).
TREM1 was signiﬁcantly overexpressed in macrophages
from CCPA patients as compared with those from healthy
subjects at baseline (2.31-fold, p 0.0006). After stimulation
with A. fumigatus, expression remained higher in the CCPA
group at all time-points (Fig. 1).
Genetic association in CCPA
Six SNPs in ﬁve genes were associated with CCPA (p <0.05),
including a missense non-synonymous coding SNP in TLR1
(rs4833095) and a CLEC7A SNP (rs7309123) previously
associated with IA [20]. Three associations (DENND1B
rs2477077, PLAT rs8178890, and VEGFA rs10434) remained
signiﬁcant after correction for multiple testing (Table 3; Fig. 2).
The TLR1 rs4833095 and CLEC7A rs7309123 associations did
not survive correction for multiple testing (false discovery rate
p 0.065). For further detail of SNPs implicated in CCPA, see
Table S2.
No SNPs in TLR3, TLR10 or TREM1 were associated with
CCPA (see Table S1 for the SNPs tested). Two SNPs
previously associated with IA (PLG rs4252125 and CLEC7A
rs16910526) were not associated with CCPA (Table S3).
Discussion
TLR2, TLR4 and TLR9 have long been known to be involved in
the recognition of A. fumigatus [3,6]. More recently, studies
have suggested that TLR1, TLR3 and TLR6 may also be
involved [4,5]. Studies have investigated expression of the
genes encoding these proteins in cells from healthy donors
[4,6,17]; however, few have investigated expression in cells
from CCPA patients. We used MDMs from CCPA patients
and healthy donors, and investigated gene expression both
before and after stimulation with live A. fumigatus, at various
time-points when different fungal morphologies predominate
TABLE 1. Characteristics of patients and controls for
genetic association experiments
Characteristic CCPA Healthy
n 112 279
Age (years), median (IQR) 64.9 (59.4–70.8) 47.0 (44.2–50.5)
Males (%) 60.7 40.1
Positive fungal culture, % (no.) 25.9 (29/112) NA
Aspergillus fumigatus 79.3 (24/29) NA
Aspergillus niger 3.4 (1/29) NA
Other Aspergillus species 3.4 (1/29) NA
Penicillium speciesa 13.8 (4/29) NA
Aspergilloma presence, % (no.)
CCPA without aspergilloma 60.7 (68/112) NA
CCPA with aspergilloma 39.3 (44/112) NA
Bronchiectasisb, % (no.) 25.9 (29/112) NA
Underlying disease, % (no.)
COPD and/or emphysema ( bullae) 44.6 (50/112) NA
Pneumoniac 20.5 (23/112) NA
Pneumothorax ( bullae) 20.5 (23/112) NA
Thoracic surgery 19.6 (22/112) NA
Classical tuberculosis 17.9 (20/112) NA
Non-tuberculous mycobacterial
infection (atypical TB)
12.5 (14/112) NA
Lung cancer survivor 11.6 (13/112) NA
Asbestos related pleural plaques 10.7 (12/112) NA
Asthma 8.9 (10/112) NA
Sarcoidosis 8.0 (9/112) NA
Otherd 5.4 (6/112)d NA
Rheumatoid arthritis 4.5 (5/112) NA
Ankylosing spondylitis/kyphoscoliosise 3.6 (4/112)e NA
No underlying disease identiﬁed 1.8 (2/112) NA
CCPA, chronic cavitary pulmonary aspergillosis; COPD, chronic obstructive
pulmonary disease; IQR, interquartile range; NA, Not Applicable; TB, tuberculosis.
aPresumed airway colonization, rather than the causative agent of CCPA.
bBronchiectasis is considered to be a co-existing, rather than underlying, disease in
CCPA.
cCommunity-acquired pneumonia requiring hospitalization.
dIncludes alcohol excess (3), chest radiotherapy without lung cancer (1),
dextrocardia (1), and smoke inhalation (1).
eAnkyolysis spondylitis (1) and kyphoscoliosis (3).
TABLE 2. Characteristics of patients and controls used for
gene expression experiments
Characteristic CCPA Healthy
n 10 10
Age (years), median (IQR) 59.0 (55.8–68.9) 38.0 (31.2–51.1)
Males, % (no.) 70 (7/10) 40 (4/10)
Aspergilloma, % (no.) 60 (6/10) NA
Positive fungal culture, % (no.) 50 (5/10) NA
Aspergillus fumigatus, % (no.) 100 (5/5) NA
Bronchiectasis, % (no.) 30 (3/10) NA
Underlying disease, % (no.)
COPD and/or
emphysema ( bullae)
30 (3/10) NA
Previous pneumoniaa 30 (3/10) NA
Previous pneumothorax
( bullae)
20 (2/10) NA
Previous thoracic surgery 20 (2/10) NA
Previous classic TB 20 (2/10) NA
Previous non-tuberculous
mycobacterial infection (atypical TB)
10 (1/10) NA
Lung cancer survivor 10 (1/10) NA
Previous asbestos exposure/asbestosis 10 (1/10) NA
Sarcoidosis 20 (2/10) NA
Other (alcohol excess) 10 (1/10) NA
CCPA, chronic cavitary pulmonary aspergillosis; COPD, chronic obstructive
pulmonary disease; NA, Not Applicable; IQR, interquartile range; TB, tuberculosis.
aCommunity-acquired pneumonia requiring hospitalization.
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(0.5–3 h, conidia; 6 h, germ-tubes; 9 h, hyphae [18]). We have
shown that expression of TLRs in MDMs from CCPA patients
is dramatically different from expression in MDMs from
healthy donors.
Our results for TLR2 and TLR4 expression in the healthy
group are broadly similar to previous ﬁndings obtained with
various cell types from healthy individuals [4,6,17]; however,
we found that expression of these TLRs (TLR2 in particular)
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FIG. 1. Expression of the Toll-like
receptor (TLR) and the triggering
receptor expressed on myeloid cells 1
(TREM1) genes differs between
monocyte-derived macrophages from
chronic cavitary pulmonary aspergillosis
patients (open circles) and healthy
subjects (closed squares). Fold difference
is calculated relative to the healthy 0-h
value. p-Values indicate the differences in
the change over time between the two
groups, calculated by repeated measures
two-way ANOVA. Mean and standard
deviations are shown. Each group
comprises ten pooled RNA samples.
Mean and standard deviations are shown
for the three replicates performed. NS,
not signiﬁcant.
TABLE 3. Single-nucleotide polymorphisms (SNPs) associated with chronic cavitary pulmonary aspergillosis (CCPA)
Gene SNP
Alleles
(M/m) Model for association
Genotype frequency
OR (95% CI) p-Value
FDR
p-value LocationGenotype
CCPA,
no. (%)
Healthy,
no. (%)
TLR1 rs4833095 A/G AG + GG vs. AA AA
AG + GG
83 (74.1)
29 (25.9)
173 (62.5)
104 (37.5)
0.58 (0.36–0.95) 0.029 0.065 Exonic
(Asn/Ser)
CLEC7A (dectin-1) rs7309123 C/G CC + GC vs. GG GG
CC + GC
30 (27.0)
81 (73.0)
49 (17.9)
225 (82.1)
0.59 (0.35–0.99) 0.046 0.099 Intronic
PLAT rs8178890 G/A AA + GA vs. GG GG
AA + GA
105 (93.8)
7 (6.3)
237 (84.9)
42 (15.1)
0.38 (0.16–0.86) 0.021 0.049 Intronic
rs879293 G/A AA + GA vs. GG GG
AA + GA
29 (25.9)
83 (74.1)
102 (36.6)
177 (63.4)
1.65 (1.01–2.69) 0.044 0.097 Intronic
DENND1B rs2477077 C/T CC + CT vs. TT TT
CC + CT
11 (9.8)
101 (90.2)
10 (3.6)
269 (96.4)
0.34 (0.14–0.83) 0.017 0.041 Intronic
VEGFA rs10434 G/A GG + AG vs. AA AA
GG + AG
15 (13.4)
97 (86.6)
69 (24.7)
210 (75.3)
2.12 (1.16–3.90) 0.015 0.036 30-UTR
FDR, false discovery rate; M/m, major allele/minor allele; UTR, untranslated region.
p-Values were calculated for the model indicated by the use of logistic regression in Stata. Risk alleles are shown in bold. SNPs in bold remained signiﬁcant after Benjamini–
Hochberg adjustment for FDR (FDR-adjusted p-values are shown).
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was higher in the CCPA group than in the healthy group after
stimulation with A. fumigatus, and remained higher when
expression decreased in the healthy group at 9 h. TLR3
expression in the healthy group showed a similar decrease at
9 h, whereas TLR9 expression in this group increased at this
time-point. The changes in expression at the 9-h time-point
were much less dramatic, or did not occur at all, in the CCPA
group, and may represent a healthy response to the hyphal
form (which is dominant after 9 h of co-culture [18]), or a
response to long-term fungal exposure, which did not occur in
the CCPA group. TLR9 expression, in particular, appeared not
to respond to the presence of A. fumigatus until 9 h, which
may suggest that, in MDMs, this TLR does not respond to
conidia or germ-tubes (the dominant fungal morphologies for
the ﬁrst 6 h of co-culture [18]), but only to hyphae. This differs
from the results of studies with neutrophils from healthy
donors [6]. As well as using different cell types, many previous
studies have used killed fungi, whereas we used live A. fumig-
atus. The use of live fungus is important, as individuals are
exposed to live fungal spores in the environment, and live
A. fumigatus is cultured from patients, but limits the duration of
the experiment to 9 h, because, after this time, the fungus
overgrows the plate and the MDMs. This can be avoided by
increasing the MDM/conidia ratio; however, we chose to use
the 1 : 2 ratio in an attempt to ensure that all MDMs were
experiencing fungal stimulation. In addition, at lower ratios, the
MDMs destroy the conidia before germination, whereas the
use of our methodology allows germination to occur such that
the different time-points are representative of exposure to
different live fungal morphologies [18]. These differences in
methodology may help to explain the differences between our
results and those of previous studies.
Expression of TLR3 and TLR10 increased only slightly after
initial exposure to A. fumigatus, which is similar to the results
of previous studies [4,6]; however, we demonstrated that
baseline expression of these genes was signiﬁcantly lower in
the CCPA group, consistent with a role for these TLRs in
protection against aspergillosis and of reduced constitutive
expression with susceptibility. In addition to this, TREM1
expression was found to be increased in MDMs from CCPA
patients at baseline, and continued to be increased at all
time-points after stimulation with A. fumigatus.
Recent studies have suggested a role for TLR3 in epithelial
cell-mediated protection against A. fumigatus [4,21], and TLR10
is known to form heterodimers with TLR1 and TLR2 [22,23].
TREM1 is an activating receptor found on neutrophils and
monocytes that ampliﬁes the inﬂammation induced by stimu-
lation of TLRs, including TLR2 and TLR4 [7,8]. TLR2 and TLR4
are important in the response to A. fumigatus, and TLR10 and
TREM1 may play a role in the response to A. fumigatus via
interactions with these. Deﬁciency in baseline expression of
TLRs may affect susceptibility to CCPA by reducing the
early-stage recognition of A. fumigatus and reducing an other-
wise appropriate immune response. The increased expression
of TREM1 may be an attempt to combat this.
We acknowledge that, within the host, multiple cells are
involved in the response to infection, including non-traditional
immune cells such as epithelial cells [24], and that, among
traditional immune cells, the alveolar macrophage would be the
ideal cell type in which to study these interactions between host
and pathogen; however, as discussed previously, the use of
MDMs prevents the population being skewed in favour of mild
CCPA, which would have occurred had we recruited only
bronchoscopy-ﬁt subjects [18]. The use of pooled samples for
FIG. 2. Genotype frequencies of
single-nucleotide polymorphisms
associated with chronic cavitary
pulmonary aspergillosis (CCPA): 279
healthy subjects and 112 CCPA patients
were genotyped successfully. rs3917354 is
an insertion–deletion mutation.
DENND1B, DENN/MADD domain
containing 1B; VEGFA, vascular
endothelial growth factor A.
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gene expression experiments has also been discussed previously
[18]. Although the use of these prevents analysis of interpatient
variability, it allows for the analysis of a greater number of genes
(owing to the limited availability of patient cells). It is likely that
mean values for cases and controls would be broadly similar to
those obtained with pooled samples; however, we appreciate
that it is possible that our pooled value could be skewed by a
minority of individuals. In addition,we acknowledge thatwe have
used a single fungal isolate and inoculum for these experiments,
in cells from multiple individuals. This is because we were
interested in the differences between patients and controls
rather than in differences between fungal isolates; however, we
appreciate that different fungal isolates/strains may produce
different gene expression responses, and that this would be
interesting to investigate in future.
We have not yet performed functional assays to support the
gene expression studies presented here. In particular, a
functional study that correlates phenotypic expression with
function would be beneﬁcial in the future, as would validation
of the gene expression results by measurement of protein
levels to conﬁrm that differences in expression are translated
into differences in protein levels. However, this is predomi-
nantly a hypothesis-generating study, and, despite these
limitations, we feel that the results presented here suggest
that expression of TLRs differs between MDMs from CCPA
patients and those from healthy subjects, both before and after
stimulation with A. fumigatus, and that this initial ﬁnding merits
further, more detailed investigation. In particular, we believe
that our results support studies suggesting roles for TLRs
other than TLR2, TLR4 and TLR9 in the recognition and
response to A. fumigatus.
Given the importance of TLRs in A. fumigatus recognition,
and the expression results presented here, it seems likely that
SNPs in TLR genes affect aspergillosis susceptibility. Indeed,
SNPs in TLR1 (rs5743611 and rs4833095), TLR4 (rs4986790
and rs4986791) and TLR6 (rs5743611) were previously
associated with IA, and one SNP in TLR4 (rs4986790) was
previously associated with CCPA [5,15,16]. Despite this, only
one TLR SNP, in TLR1 (rs4833095), was identiﬁed as being
associated with CCPA in the current study, and this associ-
ation did not remain signiﬁcant after correction for multiple
testing. This SNP was previously associated with IA [5].
Unfortunately, the previously associated TLR4 SNP failed
primer design and was not genotyped.
TLR1 forms heterodimers with TLR2 [5,25] that recognize
and respond to A. fumigatus [6]. SNPs in TLR1 that affect TLR1
expression, structure, or function, especially those that affect
heterodimer formation with TLR2, may affect the response to
A. fumigatus, and could affect susceptibility. rs4833095 is a
non-synonymous coding SNP, and may have effects such as
these. rs4833095 has been associated with a variety of
diseases, and is in high linkage disequilibrium (LD; r2 > 0.8)
with many other SNPs (Table S2).
Despite a disappointing lack of association between TLR
SNPs and CCPA, other associations were identiﬁed. SNPs in
VEGFA, DENND1B and PLAT remained signiﬁcantly associated
with CCPA after correction for multiple testing. These are
novel and important ﬁndings; these genes are not currently
considered to be major candidates for aspergillosis suscepti-
bility, and our results suggests novel hypotheses and novel
areas for future research into this disease. Two of these SNPs
are in intronic regions, which are traditionally described as
non-functional DNA; however, recent research (e.g. the
ENCODE project) suggests that these regions could indeed
be functional [26]. Therefore, these SNPs, or those in LD
with them, could indeed be important for susceptibility to
CCPA.
VEGFA is a key mediator of angiogenesis, a process
by which new blood vessels are formed [27]. Excessive
small-vessel proliferation is a feature of CCPA, and may lead to
haemoptysis. Angiogenesis can be inhibited by A. fumigatus, and
inhibition of VEGFA may increase susceptibility to IA [11,12].
In contrast, expression of VEGFA is increased within asperg-
illomas, possibly because of hypoxia within these structures
[27,28]. Recently, VEGFA has also been shown to have
synergistic effects with antifungals in a murine model of acute
aspergillosis [29]. Multiple isoforms of VEGFA, with varying
degrees of angiogenic potential, are produced by alternative
splicing [27,30]. SNPs in VEGFA may affect this alternative
splicing and alter the isoform levels within the tissues.
Alternatively, SNPs may affect the angiogenic ability of VEGFA.
The 30-untranslated region SNP identiﬁed was previously
associated with measures of lung function [31]. Further work
is required to determine how this SNP or those in high LD
with it alter the protein expression or function, but the ﬁnding
of an association with CCPA supports a role for angiogenesis
and VEGFA in susceptibility to this disease.
DENND1B is a negative regulator of TNFR1, which is
expressed by many immune cells, including monocytes and
bronchial epithelial cells [10]. It binds to TNFR1, suppressing
downstream signalling to modulate the Th1/Th2 response and
inﬂammatory cytokine production of cells [10,32]. TNF-a is
produced by macrophages and other immune cells in response
to A. fumigatus, and is important in the clearance of A. fumig-
atus conidia and in neutrophil recruitment and cytokine
production in response to this fungus. In one small study,
the high TNF-a-producing genotype 308A/A was found to be
reduced in allergic aspergillosis and CCPA patients as
compared with controls, suggesting that reduced TNF-a
responses are linked to aspergillosis susceptibility [14]. Sup-
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pression of TNFR1 by DENND1B may affect susceptibility to
aspergillosis by suppressing TNF-a-driven Th1 responses.
PLAT is a plasminogen activator that promotes the
conversion of plasminogen to plasmin [17]. Plasminogen has
recently been suggested to play a role in the response to
A. fumigatus, and in susceptibility to aspergillosis [9,17]. It binds
to A. fumigatus in a dose-dependent manner, and can be
converted to plasmin while bound [9]. Variations within the
PLG gene may inﬂuence the pathogenesis of IA in both mice
and humans [9]. In this context, plasmin appears to act as a
chemoattractant for monocytes and induce expression of
inﬂammatory cytokines and chemokines by these cells [33,34].
SNPs in PLAT may inﬂuence susceptibility to aspergillosis by
affecting the conversion of plasminogen to plasmin in response
to A. fumigatus.
Our CCPA study population is the largest used for genetic
association studies to date, despite containing only 112
patients. Many previous studies have involved only a handful
of patients. This is because of the relatively rare nature of
CCPA. Our patients were recruited from the NAC, which
receives referrals from across the UK. The majority of CCPA
patients have (often multiple) past or present underlying
conditions [2], and selection of a control population presents
a challenge. This has been discussed previously [18]. Ideally, a
matched control subject with the same underlying diseases for
each case should be recruited; however, this is practically
impossible, and, consequently, healthy control populations
have been used in all previous CCPA genetic association
studies [13,15,18,35]. We also used healthy unmatched
controls, acknowledging that, rather than increasing our
power to ﬁnd genetic associations with CCPA, this reduces
it, and therefore does not invalidate our ﬁndings. In addition,
the control population is younger than the CCPA population,
and some controls could, in time, develop CCPA; however,
this would, again, reduce rather than increase our power. As
each underlying disease occurs in only a minority of cases, it is
unlikely that any genetic associtations identiﬁed were related
to an underlying disease rather than to CCPA. However, to
investigate this, we compared our results with those of
studies on genetic association in TB (the most common
primary underlying disease in CCPA [2]; Appendix S2). Our
study included SNPs that have been associated with TB
previously [36]. None of these remained signiﬁcantly associ-
ated with CCPA after correction for multiple testing,
suggesting that the observed associations were not affected
by a lack of matching for previous TB. We restricted the
current study to Caucasians, in order to allow accurate
comparison between cases and controls, and acknowledge
that this limits the generalizability of our ﬁndings to this
particular ethnic group. Further work in other ethnic groups
would be required to determine the factors involved in
susceptibility within these groups.
The novel associations presented here, including those with
PLAT, DENND1B, and VEGFA, require replication in other
populations and validation in functional studies in order to
conﬁrm them as plausible candidates for susceptibility to
CCPA; however, their identiﬁcation in this hypothesis-gener-
ating study suggests novel areas for future research, and
increases our understanding of the factors inﬂuencing CCPA
susceptibility and pathogenesis. In addition, the deﬁcient
constitutive expression of TLR3 and TLR10 demonstrated
may increase susceptibility to CCPA by reducing the recog-
nition of and response to A. fumigatus. Future work will
increase this understanding further, and allow the identiﬁcation
of susceptible individuals or the development of treatments to
combat deﬁcient responses in CCPA patients.
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